Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) ...
Glatiramer acetate (Copaxone) is an injectable drug that treats relapsing forms of multiple sclerosis in adults. It’s a man-made version of a protein similar to one found in myelin, an insulating ...
KANSAS CITY, Mo. (November 15, 2005) -- Clinical research data published in the December issue of Multiple Sclerosis provided evidence that COPAXONE® (glatiramer acetate injection) may offer ...
Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback